We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 29, 2020

Ibrutinib Added to 10-Day Decitabine for Older Patients With AML and Higher-Risk MDS

Blood advances

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood advances
Ibrutinib Added to 10-Day Decitabine for Older Patients With AML and Higher Risk MDS
Blood Adv 2020 Sep 22;4(18)4267-4277, G Huls, DA Chitu, T Pabst, SK Klein, G Stussi, L Griskevicius, PJM Valk, J Cloos, AA van de Loosdrecht, D Breems, D van Lammeren-Venema, I van Zeventer, R Boersma, M Jongen-Lavrencic, M Fehr, M Hoogendoorn, MG Manz, M Söhne, R van Marwijk Kooy, D Deeren, MWM van der Poel, MC Legdeur, L Tick, Y Chalandon, E Ammatuna, S Blum, B Löwenberg, GJ Ossenkoppele

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading